InnovAge Holding Past Earnings Performance
Past criteria checks 0/6
InnovAge Holding's earnings have been declining at an average annual rate of -33.4%, while the Healthcare industry saw earnings growing at 6.2% annually. Revenues have been growing at an average rate of 7.1% per year.
Key information
-33.4%
Earnings growth rate
-31.5%
EPS growth rate
| Healthcare Industry Growth | 8.5% |
| Revenue growth rate | 7.1% |
| Return on equity | -7.7% |
| Net Margin | -2.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is InnovAge Holding (NASDAQ:INNV) A Risky Investment?
Aug 20
InnovAge Holding Corp.'s (NASDAQ:INNV) Shares Leap 30% Yet They're Still Not Telling The Full Story
Jun 28Sentiment Still Eluding InnovAge Holding Corp. (NASDAQ:INNV)
May 07InnovAge Holding (NASDAQ:INNV) Has Debt But No Earnings; Should You Worry?
Mar 15Market Still Lacking Some Conviction On InnovAge Holding Corp. (NASDAQ:INNV)
Jan 06InnovAge Holding Corp.'s (NASDAQ:INNV) Intrinsic Value Is Potentially 73% Above Its Share Price
Aug 10Cautious Investors Not Rewarding InnovAge Holding Corp.'s (NASDAQ:INNV) Performance Completely
Jun 08InnovAge GAAP EPS of -$0.09 misses by $0.06, revenue of $172.86M misses by $1.11M
Sep 13InnovAge names Richard Feifer as chief medical officer
Aug 17InnovAge Holding (NASDAQ:INNV) Could Be Struggling To Allocate Capital
Jul 27Earnings Miss: InnovAge Holding Corp. Missed EPS And Analysts Are Revising Their Forecasts
May 12Here's What's Concerning About InnovAge Holding's (NASDAQ:INNV) Returns On Capital
Apr 14Is There An Opportunity With InnovAge Holding Corp.'s (NASDAQ:INNV) 30% Undervaluation?
Mar 24InnovAge Pursues Compliance As Precursor To Post-Pandemic Growth
Mar 19InnovAge Holding's (NASDAQ:INNV) Robust Earnings Are Supported By Other Strong Factors
Nov 16Are Investors Undervaluing InnovAge Holding Corp. (NASDAQ:INNV) By 48%?
Jul 28Revenue & Expenses Breakdown
How InnovAge Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 764 | -21 | 539 | 0 |
| 31 Mar 24 | 741 | -31 | 530 | 0 |
| 31 Dec 23 | 721 | -32 | 519 | 0 |
| 30 Sep 23 | 699 | -38 | 513 | 0 |
| 30 Jun 23 | 688 | -41 | 510 | 0 |
| 31 Mar 23 | 684 | -42 | 511 | 0 |
| 31 Dec 22 | 689 | -38 | 518 | 0 |
| 30 Sep 22 | 697 | -27 | 518 | 0 |
| 30 Jun 22 | 699 | -7 | 505 | 0 |
| 31 Mar 22 | 697 | 13 | 493 | 0 |
| 31 Dec 21 | 676 | 5 | 463 | 0 |
| 30 Sep 21 | 658 | 13 | 432 | 0 |
| 30 Jun 21 | 638 | -44 | 405 | 0 |
| 31 Mar 21 | 619 | -38 | 375 | 0 |
| 31 Dec 20 | 607 | -20 | 365 | 0 |
| 30 Sep 20 | 585 | -26 | 355 | 0 |
| 30 Jun 20 | 567 | 26 | 350 | 0 |
| 30 Jun 19 | 466 | 20 | 287 | 0 |
Quality Earnings: INNV is currently unprofitable.
Growing Profit Margin: INNV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INNV is unprofitable, and losses have increased over the past 5 years at a rate of 33.4% per year.
Accelerating Growth: Unable to compare INNV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INNV is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (6%).
Return on Equity
High ROE: INNV has a negative Return on Equity (-7.75%), as it is currently unprofitable.